<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04327765</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC 010-102</org_study_id>
    <nct_id>NCT04327765</nct_id>
  </id_info>
  <brief_title>Staccato® Granisetron Multiple Dose PK</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of Staccato Granisetron (AZ-010) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the tolerability and safety of AZ-010 following 7 days of dosing (up to 3 mg) in
      healthy volunteers To characterize the pharmacokinetics of AZ-010 following 7 days of dosing
      (up to 3 mg) in healthy volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and
      Pharmacokinetic Profile of Staccato Granisetron (AZ-010) in Healthy Volunteers
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]).</measure>
    <time_frame>8 days</time_frame>
    <description>Number of Subjects with Adverse Events as a measure of Safety and Tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of Granisetron Exposure in Plasma</measure>
    <time_frame>8 days</time_frame>
    <description>AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Granisetron Maximum exposure in Plasma</measure>
    <time_frame>8 days</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Granisetron Time to Maximum Exposure in Plasma</measure>
    <time_frame>8 days</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single orally-inhaled dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single orally-inhaled dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single orally-inhaled dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>0.5mg AZ-010</intervention_name>
    <description>Subject will receive a single inhaled dose (0.5mg) of AZ-010 or matching Staccato Placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Staccato Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>1mg AZ-010</intervention_name>
    <description>Subject will receive a single inhaled dose (1mg) of AZ-010 or matching Staccato Placebo</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Staccato Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>3mg AZ-010</intervention_name>
    <description>Subject will receive a single inhaled dose (3mg) of AZ-010 or matching Staccato Placebo</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Staccato Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy based on a medical evaluation including history, physical examination, vital
             signs, electrocardiograms (ECGs) and laboratory tests assessed at the screening visit
             and prior to the first dose of study drug.

          -  Body weight ≥ 50 kg and BMI within the range of 18 to 32 kg/m2, inclusive, at
             screening.

          -  Negative urine tests for selected drugs of abuse and alcohol breath test at screening
             and Day 1.

        Exclusion Criteria:

          -  Any significant medical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry O'Reilly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatjana Naranda, PhD</last_name>
    <phone>650-944-7700</phone>
    <email>tnaranda@alexza.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barrie Weeks, BA</last_name>
    <phone>650-944-7156</phone>
    <phone_ext>133</phone_ext>
    <email>bweeks@alexza.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Eichler</last_name>
      <phone>602-437-0097</phone>
      <email>blake.eichler@celerion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

